Moderna, Inc. M1RN34.SA Stock
Moderna, Inc. Price Chart
Moderna, Inc. M1RN34.SA Financial and Trading Overview
| Moderna, Inc. stock price | 27.2 BRL |
| Previous Close | 30.49 BRL |
| Open | 0 BRL |
| Bid | 31.02 BRL x N/A |
| Ask | 31.14 BRL x N/A |
| Day's Range | 0 - 0 BRL |
| 52 Week Range | 0 - 57.57 BRL |
| Volume | 0 BRL |
| Avg. Volume | 61.55K BRL |
| Market Cap | 240.08B BRL |
| Beta (5Y Monthly) | 1.697464 |
| PE Ratio (TTM) | 10.83737 |
| EPS (TTM) | -3.14 BRL |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
M1RN34.SA Valuation Measures
| Enterprise Value | 111.58B BRL |
| Trailing P/E | 10.83737 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 15.942939 |
| Price/Book (mrq) | 6.375962 |
| Enterprise Value/Revenue | 7.41 |
| Enterprise Value/EBITDA | 21.565 |
Trading Information
Moderna, Inc. Stock Price History
| Beta (5Y Monthly) | 1.697464 |
| 52-Week Change | -6.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 57.57 BRL |
| 52 Week Low | 0 BRL |
| 50-Day Moving Average | 33.52 BRL |
| 200-Day Moving Average | 39.81 BRL |
M1RN34.SA Share Statistics
| Avg. Volume (3 month) | 61.55K BRL |
| Avg. Daily Volume (10-Days) | 79.92K BRL |
| Shares Outstanding | 7.62B |
| Float | 3.44B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.0030% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 31.76% |
| Operating Margin (ttm) | 32.05% |
| Gross Margin | 39.81% |
| EBITDA Margin | 34.35% |
Management Effectiveness
| Return on Assets (ttm) | 11.66% |
| Return on Equity (ttm) | 26.62% |
Income Statement
| Revenue (ttm) | 15.06B BRL |
| Revenue Per Share (ttm) | 3.86 BRL |
| Quarterly Revenue Growth (yoy) | -69.29% |
| Gross Profit (ttm) | 10.55B BRL |
| EBITDA | 5.17B BRL |
| Net Income Avi to Common (ttm) | 4.78B BRL |
| Diluted EPS (ttm) | 2.89 |
| Quarterly Earnings Growth (yoy) | -97.79% |
Balance Sheet
| Total Cash (mrq) | 8.92B BRL |
| Total Cash Per Share (mrq) | 2.34 BRL |
| Total Debt (mrq) | 1.11B BRL |
| Total Debt/Equity (mrq) | 5.87 BRL |
| Current Ratio (mrq) | 3.464 |
| Book Value Per Share (mrq) | 4.9122 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 993M BRL |
| Levered Free Cash Flow (ttm) | 541.88M BRL |
Profile of Moderna, Inc.
| Country | Brazil |
| State | MA |
| City | Cambridge |
| Address | 200 Technology Square |
| ZIP | 02139 |
| Phone | 617 714 6500 |
| Website | https://www.modernatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3900 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Moderna, Inc. Stock
What is a current M1RN34.SA stock price?
Moderna, Inc. M1RN34.SA stock price today per share is 27.2 BRL.
How to purchase Moderna, Inc. stock?
You can buy M1RN34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Moderna, Inc.?
The stock symbol or ticker of Moderna, Inc. is M1RN34.SA.
Which industry does the Moderna, Inc. company belong to?
The Moderna, Inc. industry is Biotechnology.
How many shares does Moderna, Inc. have in circulation?
The max supply of Moderna, Inc. shares is 7.66B.
What is Moderna, Inc. Price to Earnings Ratio (PE Ratio)?
Moderna, Inc. PE Ratio is now.
What was Moderna, Inc. earnings per share over the trailing 12 months (TTM)?
Moderna, Inc. EPS is -3.14 BRL over the trailing 12 months.
Which sector does the Moderna, Inc. company belong to?
The Moderna, Inc. sector is Healthcare.